Clinical study on the efficacy and safety of intravenous itraconazole infusion for the treatment of invasive fungal infection in China

Japanese Journal of Infectious Diseases

Volumn 59, Issue 6, 2006, Pages 370-376

  Wang, Aixia ^a   Zhang, Yingyuan ^b   He, Lixian ^b   Shen, Zhixiang ^c   Liao, Wanqing ^d   Han, Mingzhe ^e   Li, Ruoyu ^f   Liang, Derong ^g   Wu, Shaoxi ^h   Hahn Ast, Corinna ⁱ   Glasmacher, Axel ⁱ   Liekwok, Wai Albert ^j  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^f PEKING UNIVERSITY FIRST HOSPITAL   (China)

^g SICHUAN UNIVERSITY   (China)

^h PEKING UNION MEDICAL COLLEGE   (China)

ⁱ UNIVERSITY OF BONN   (Germany)

^j UNIVERSITY OF HONG KONG   (Hong Kong)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CIPROFLOXACIN; ITRACONAZOLE;

ABDOMINAL DISCOMFORT; ADULT; AGED; ANOREXIA; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASTHMA; BILE DUCT DISEASE; BILIRUBIN BLOOD LEVEL; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRYPTOCOCCUS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHIL COUNT; FEMALE; FLU LIKE SYNDROME; FUNGAL MENINGITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HEART PALPITATION; HEMOLYTIC ANEMIA; HISTOPLASMA; HUMAN; HYPOKALEMIA; KIDNEY FAILURE; LEUKOCYTE COUNT; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NAUSEA; NAUSEA AND VOMITING; OPEN STUDY; PERITONITIS; PHASE 4 CLINICAL TRIAL; SEPSIS; SIDE EFFECT; SOFT TISSUE INFECTION; THORAX PAIN; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL; WOUND INFECTION;

EID: 33845969157     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: 10.7883/yoken.jjid.2006.370     Document Type: Article

References (47)

1. Maertens, J., Vrebos, M. and Boogaerts, M. (2001): Assessing risk factors for systemic fungal infections. Eur. J. Cancer Care (Engl.), 10, 56-62.
2. Boyle, B.M. and McCann, S.R. (2000): The use of itraconazole as prophylaxis against invasive fungal infection in blood and marrow transplant recipients. Transpl. Infect. Dis., 2, 72-79.
3. Groll, A., Shah, P.M., Mentzel, C., Schneider, M., Just-Nübling, G. and Hübner, G. (1996): Trends in the post-mortem epidemiology of invasive fungal infections at a university hospital. J. Infect., 33, 23-32.
4. McNeil, M.M., Nash, S.L., Hajjeh, R.A., Phelan, M.A., Conn, L.A., Plikaytis, B.D. and Warnock, D.W. (2001): Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis., 33, 641-647.
5. Liu, Z.Y., Sheng, R.Y., Li, X.L., Li, T.S. and Wang, A.X. (2003): Nosocomial fungal infections, analysis of 149 cases. Zhonghua Yi. Xue. Za Zhi., 83, 399-402 (in Chinese).
6. Fan, H. and Wang, A. (2003): Clinical analysis on 113 cases of septicemia. Chin. J. Infect. Chemother., 3, 99-102 (in Chinese).
7. Working Party of the British Society for Antimicrobial Chemotherapy (1997): Therapy of deep fungal infection in haematological malignancy. J. Antimicrob. Chemother., 40, 779-788.
8. Kontoyiannis, D.P., Bodey, G.P. and Mantzoros, C.S. (2001): Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses, 44, 125-135.
9. Wong-Beringer, A., Jacobs, R.A. and Guglielmo, B.J. (1998): Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis., 27, 603-618.
10. Walsh, T.J., Finberg, R.W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R.N., Dummer, S., Schuster, M. and Holcenberg, J. S. (1999): Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med., 340, 764-771.
11. Bowden, R., Chandrasekar, P., White, M.H., Li, X., Pietrelli, L., Gurwith, M., van Burik, J.A., Laverdiere, M., Safrin, S. and Wingard, J.R. (2002): A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis, 35, 359-366.
12. Van Cutsem, J. (1989): The in vitro antifungal spectrum of itraconazole. Mycoses, 32, 7-13.
13. Pfaller, M.A., Boyken, L., Hollis, R.J., Messer, S.A., Tendolkar, S. and Diekema, D.J. (2005): In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J. Clin. Microbiol., 43, 3807-3810.
14. Boogaerts, M.A., Maertens, J., Van Der, G.R., Bosly, A., Michaux, J.M., van Hoof, A., Cleeren, M., Wostenborghs, R. and de Beule, K. (2001): Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob. Agents Chemother., 45, 981-985.
15. Prentice, A.G. and Glasmacher, A. (2005): Making sense of itraconazole pharmacokinetics. J. Antimicrob. Chemother., 56 Suppl. 1, i17-i22.
16. Zhou, H., Goldman, M., Wu, J., Woestenborghs, R., Hassell, A.E., Lee, P., Baruch, A., Pesco-Koplowitz, L., Borum, J. and Wheat, L.J. (1998): A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J. Clin. Pharmacol., 38, 593-602.
17. Caillot, D., Bassaris, H., McGeer, A., Arthur, C., Prentice, H.G., Seifert, W. and de Beule, K. (2001): Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin. Infect. Dis., 33, e83-e90.
18. Ascioglu, S., Rex, J.H., de Pauw, B., Bennett, J.E., Bille, J., Crokaert, F., Denning, D.W., Donnelly, J.P., Edwards, J.E., Erjavec, Z., Fiere, D., Lortholary, O., Maertens, J., Meis, J.F., Patterson, T.F., Ritter, J., Selleslag, D., Shah, P.M., Stevens, D.A. and Walsh, T.J. (2002): Defining opportunistic invasive fungal infections in immuno-compromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis., 34, 7-14.
19. Pappas, P.G., Rex, J.H., Lee, J., Hamill, R.J., Larsen, R.A., Powderly, W., Kauffman, C.A., Hyslop, N., Mangino, J.E., Chapman, S., Horowitz, H.W., Edwards, J.E. and Dismukes, W.E. (2003): A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis., 37, 634-643.
20. Pfaller, M.A., Jones, R.N., Doern, G.V., Sader, H.S., Messer, S.A., Houston, A., Coffman, S., Hollis, R.J. and The SENTRY participant group (2000): Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob. Agents Chemother., 44, 747-751.
21. Abi Said, D., Anaissie, E., Uzun, O., Raad, I., Pinzcowski, H. and Vartivarian, S. (1997): The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis., 24, 1122-1128.
22. Hu, Y.F., He, J., Chen, G.L., Wang, D., Liu, Z.Q., Zhang, C., Duan, L.F. and Zhou, H.H. (2005): CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin. Chim. Acta, 353, 187-192.
23. Pang, Y.S., Wong, L.P., Lee, T.C., Mustafa, A.M., Mohamed, Z. and Lang, C.C. (2004): Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. Br. J. Clin. Pharmacol., 58, 332-335.
24. Kitada, M. (2003): Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. Int. J. Clin. Pharmacol. Res., 23, 31-35.
25. Zhu, B., Chen, G.L., Chen, X.P., He, N., Liu, Z.Q., Jiang, C.H., Wang, D. and Zhou, H.H. (2002): Genotype of CYP3AP1 associated with CYP3A activity in Chinese Han population. Acta Pharmacol. Sin., 23, 567-572.
26. Shu, Y., Cheng, Z.N., Liu, Z.Q., Wang, L.S., Zhu, B., Huang, S.L., Ou-Yang, D.S. and Zhou, H.H. (2001): Interindividual variations in levels and activities of cytochrome P-450 in liver microsomes of Chinese subjects. Acta Pharmacol. Sin., 22, 283-288.
27. Zhou, H.H. and Liu, Z.Q. (2000): Ethnic differences in drug metabolism. Clin. Chem. Lab. Med., 38, 899-903.
28. Boogaerts, M., Winston, D.J., Bow, E.J., Garber, G., Reboli, A.C., Schwarer, A.P., Novitzky, N., Boehme, A., Chwetzoff, E. and de Beule, K. (2001): Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann. Intern. Med., 135, 412-422.
29. de Beule, K., de Doncker, P., Cauwenbergh, G., Koster, M., Legendre, R., Blatchfords, N., Daunas, J. and Chwestoff, E. (1988): The treatment of aspergillosis and aspergilloma with itraconazole, clinical results in an open international study (1982-1987). Mycoses, 31, 476-485.
30. van't Wout, J.W., Novakova, I., Verhagen, C.A.H., Fibbe, W.E., de Pauw, B.E. and van der Meer, J.W.M. (1991): The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J. Infect., 22, 45-52.
31. Denning, D.W., Tucker, R.M., Hanson, L.H. and Stevens, D.A. (1989): Treatment of invasive aspergillosis with itraconazole. Am. J. Med., 86, 791-800.
32. Denning, D.W., Lee, J.Y., Hostetler, J.S., Pappas, P., Kauffman, C.A., Dewsnup, D.H., Galgiani, C.A., Graybill, J.R., Sugar, A.M., Catanzaro, A., Gallis, H.A., Perfect, J.R., Dockery, B., Dismukes, W.E. and Stevens, D.A. (1994): NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am. J. Med., 97, 135-144.
33. Denning, D.W., Marinus, A., Cohen, J., Spence, D., Herbrecht, R., Pagano, L., Kibbler, C., Kremery, V., Offner, F., Cordonnier, C., Jehn, U., Ellis, M., Collette, L., Sylvester, R. and the EORTC Invasive Fungal Infections Cooperative Group (1998): An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. J. Infect., 37, 173-180.
34. Gonzalez, G.M., Fothergill, A.W., Sutton, D.A., Rinaldi, M.G. and Loebenberg, D. (2005): In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med. Mycol., 43, 281-284.
35. Mocherla, S. and Wheat, L.J. (2001): Treatment of histoplasmosis. Semin. Respir. Infect., 16, 141-148.
36. Lortholary, O., Denning, D.W. and Dupont, B. (1999): Endemic mycoses: a treatment update. J. Antimicrob. Chemother., 43, 321-331.
37. Saag, M.S., Graybill, R.J., Larsen, R.A., Pappas, P.G., Perfect, J.R., Powderly, W.G., Sobel, J.D. and Dismukes, W.E. (2000): Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis., 30, 710-718.
38. Chang, L., Phipps, W., Kennedy, G. and Rutherford, G. (2005): Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst. Rev., 20 (3), CD004773.
39. Abdel-Salam, H.A. (2005): In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs. Mycoses, 48, 327-332.
40. Glasmacher, A., Molitor, E., Mezger, J. and Marklein, G. (1996): Antifungal prophylaxis with itraconazole in neutropenic patients: pharmacological, microbiological and clinical aspects. Mycoses, 39, 249-258.
41. Glasmacher, A., Prentice, A., Gorschluter, M., Engelhart, S., Hahn, C., Djulbegovic, B. and Schmidt-Wolf, I.G. (2003): Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J. Clin. Oncol., 21, 4615-4626.
42. Glasmacher, A. and Prentice, A.G. (2005): Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J. Antimicrob. Chemother., 56 (Suppl. 1), i23-i32.
43. Ehninger, G., Schuler, U., Bammer, S., Aulitzky, W., Binder, C., Böhme, A., Egerer, G., Ganser, A., Peschel, C., Schwerdtfeger, R., Silling, G., Zander, A. and Wandt, H. (2002): Intravenous itraconazole followed by oral itraconazole versus intravenous amphotericin B as empirical antifungal therapy for febrile neutropenic haematological cancer patients. Blood, 100 (Suppl.), 42b.
44. Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A.L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N. and Perfect, J. (2002): Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med., 347, 2020-2029.
45. Maertens, J., Raad, I., Petrikkos, G., Boogaerts, M., Selleslag, D., Petersen, F.B., Sable, C.A., Kartsonis, N.A., Ngai, A., Taylor, A., Patterson, T.F., Denning, D.W. and Walsh, T.J. (2004): Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis., 39, 1563-1571.
46. Herbrecht, R., Denning, D.W., Patterson, T.F., Bennett, J.E., Greene, R.E., Oestmann, J.W., Kern, W.V., Marr, K.A., Ribaud, P., Lortholary, O., Sylvester, R., Rubin, R.H., Wingard, J.R., Stark, P., Durand, C., Caillot, D., Thiel, E., Chandrasekar, P.H., Hodges, M.R., Schlamm, H.T., Troke, P.F. and de Pauw, B. (2002): Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med., 347, 408-415.
47. O'Brien, S. N., Blijlevens, N. M., Mahfouz, T. H. and Anaissie, E. J. (2003): Infections in patients with hematological cancer: recent developments. Hematology (Am. Soc. Hematol. Educ. Program), 438-472.